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ABSTRACT

Potential Treatments for Malformation Associated Epilepsy
By: Olivia M. Bowles
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Anatomy and Neurobiology at Virginia Commonwealth University
Virginia Commonwealth University, 2016.
Advisor: Kimberle M Jacobs, Ph.D.
Associate Professor, Department of Anatomy and Neurobiology

Epilepsy has been previously attributed to either increased excitation or decreased
inhibition. With this closed frame of mind, modern medicine has been unable to develop
a permanent treatment against the mechanisms of epilepsy. In order to treat patients with
intractable seizures, especially those caused by developmental malformations, it is
essential to understand the entirety of mechanisms that could possibly play a role in the
abnormal cortical function.
One such developmental malformation is known as polymicrogyria.
Epileptogenesis occurs in an area laterally adjacent to this malformation known as the
paramicrogyral region (PMR). Past studies have narrowed down the potential cause of
this increased network excitation to a certain type of inhibitory interneuron, the
somatostatin (SS) interneuron. Additionally, previous studies have shown an increase in
the mGlu5 receptor on this interneurons in the PMR region only and not in control tissue,
meaning that targeting these receptors as treatment will not affect normal functioning
tissue. These results lead to our hypothesis: blockade of the mGluRs will decrease the
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activity of SS interneurons and thereby prevent the generation of epileptiform activity
and increased SS output in malformed cortex.
Utilizing the freeze-lesion model for microgyria in transgenic mice expressing
Channelrhodopsin optogenetic channels in SS interneurons, we assessed the contribution
of these SS interneurons in four different animal groups: control or PMR treated with
either Gabapentin, a current AED (antiepileptic drug), or MTEP, an mGlu5 receptor
antagonist. We tested the effects of these two drugs on SS interneuron output to
determine whether they decrease the over activation in the PMR that has been previously
studied. The following study revealed no correlation between Gabapentin-treated animals
and a decrease in epileptiform activity. Additionally, no significant difference was seen
between the MTEP-treated groups in the protocols that were measured.
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Chapter 1
Introduction to Epilepsy, Interneurons, Optogenetics, mGluRs, and Possible
Treatments
Polymicrogyria (PMG) causes intractable epilepsy, or epilepsy not
permanently treatable with medication. In order to properly treat intractable seizures,
one must understand the underlying mechanisms to target. My project focuses on a
specific receptor, the mGlu5 receptor, as the key in reducing the epileptiform activity
seen in our freeze-lesion mice that mimic the hyperexcitablilty and histopathology of
PMG. This project will aid in the search for a specific treatment for intractable
seizures as opposed to patients having to result to surgery or a continuous rotating
drug regimen.
1.1 Epilepsy – general characteristics
Epilepsy is a very common disorder that affects around 50 million people
worldwide or 1-2% of the world’s population (WHO, Epilepsy et al. 2005, Varvel,
Jiang et al. 2014) It has known to be recorded as “the falling disease” as early as 1060
BC (Varvel, Jiang et al. 2014). In addition, seizures were thought to be the work of
demons rather than a neurological condition (Varvel, Jiang et al. 2014). In 400 BC,
Hippocrates was one of the first people to characterize epilepsy as a disorder of the
brain, but he was not taken seriously. It was not until the early 1900s the first
antiepileptic drug (AED) was introduced (Varvel, Jiang et al. 2014). Today, it is
characterized as a chronic neurological disorder with characteristic seizures, or
abnormal electrical discharges, that can cause changes in emotional and motor activity
(Fisher and Saul 1997, Fisher, Arzimanoglou et al. 2014). Epilepsy can also cause
cellular and molecular changes in between seizure activity (Elger 2005). A seizure is
3

characterized as a synchronous over-activation of one or many synaptic pathways
(Varvel, Jiang et al. 2014). A consistently lowered threshold of one of these pathways
may produce epilepsy (Varvel, Jiang et al. 2014). Usually, this uncontrolled electrical
activity is the cause of too little inhibition or an increase in excitation within the
cortical network (Davies 1995).
As discussed by Fisher et al (2014), these seizures either involve specific
systems of the brain, as in the case of partial seizures, or they can be in a restricted
area and eventually spread, leading to the involvement of multiple cortical and
subcortical subunits. An epileptic seizure must have the presence or signs of
symptoms related to excess neuronal activity, or synchronous activity in the brain as
demonstrated on electroencephalogram or EEG (Fisher, Arzimanoglou et al. 2014).
Treatment with AEDs or surgery is at least partially effective in approximately
2/3 of epilepsy patients (Fisher and Saul 1997). When AEDs are ineffective, not
possible, or not desired, surgery is the last resort. For AEDs with known mechanisms,
they target ion channels and postsynaptic receptors to enhance the brain’s ability to
limit the spread of seizures (Alexander & Godwin, 2006; Fisher & Saul, 1997). AEDs
have three different modes of action, they either facilitate GABA transmission through
multiple mechanisms, they can block voltage gated ion channels which reduces
excitatory transmission, or they have an unknown/other mode of action (Davies 1995).
All AEDs treat epilepsy after it is diagnosed, but there are no successful strategies for
prevention of epilepsy for those at risk (Varvel, Jiang et al. 2014).
In more than 50% of surgery cases, however, seizures are not eliminated
completely or they are not even significantly reduced (Palmini, Gambardella et al.
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1994, Olivier, Andermann et al. 1996). If the seizure has no focal region, or a specific
area where the seizure originates, then surgery is not an option (Fisher and Saul 1997).
Ben-Ari stated that understanding and treating seizures caused by developmental
malformations requires knowledge of cortical networks and cellular mechanisms in
order to determine the mechanisms that are absent or enhanced. With this knowledge,
it is possible to understand the underlying mechanisms of the hyperexcitability that are
seen (Ben Ari 2006).
Even though some patients are treated with AEDs, 40% of patients have
seizures that are drug resistant or intractable (Fisher and Saul 1997, Alexander and
Godwin 2006). The reasons for this intractability are not fully known, but
approximately 25% of the intractable seizures are caused by malformations of cortical
development (MCDs), according to Leventer (2008). Classification of MCDs is based
on the developmental steps of cell proliferation, neuronal migration, and cortical
organization (Barkovich, Guerrini et al. 2012). These classifications span three
different groups. Group I constitutes malformations secondary to abnormal neuronal
and glial proliferation or apoptosis. Group II includes malformations that are
secondary to abnormal neuronal migration. Finally, Group III contains all the
malformations secondary to abnormal migrational and post migrational development,
as the process of cortical organization begins before the termination of neuronal
migration. Lastly, there are still MCDs that are not classified into groups (Kuzniecky
2015). Of the 25% of intractable seizures attributed to MCDs, 50% of those are
diagnosed in children (Leventer, Guerrini et al. 2008). In addition to the high
prevalence in children, as a whole, approximately 75% of patients diagnosed with a
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MCD will have epilepsy (Leventer, Guerrini et al. 2008). Thus there is a strong
connection between these errors in development and cortical hyperexcitability.
Epilepsy associated with MCDs comes about as a result of the abnormal
presence or absence of neurons or by the faulty positioning of cortical neurons
(Leventer, Guerrini et al. 2008, Varvel, Jiang et al. 2014). This misplacement or
absence can result in an imbalance between the excitatory and inhibitory neuronal
systems which would normally control this epileptiform activity and prevent these
spontaneous events from occurring (Leventer, Guerrini et al. 2008). In addition,
malformations associated with errors in development during the formation of the
cortical plate have an effect on maturation (Squier and Jansen 2010). Developmental
malformations are therefore the focus of our epilepsy studies because the biology
underlying the transition of a normal brain to a brain with epilepsy must differ from
the biology driving seizures in the epileptic brain (Varvel, Jiang et al. 2014).
1.2 Malformations – Polymicrogyria
Developmental malformations are more common than previously realized in
the past, due to the recent advancements in technology such as magnetic resonance
imaging or MRI. In fact some malformations, particularly PMG, in some cases,
require the highest current resolution of MRI (at 7T) in order to be identified (De
Ciantis, Barkovich et al. 2015).
One such malformation is known as PMG. PMG is a developmental
malformation that is present when there are multiple small convolutions on the surface
of the brain (Kuzniecky 2015). PMG is often associated with type II lissencephaly, or
“smooth brain” where there is an absence of normal convolutions (Stouffer, Golden et
6

al. 2015). The distribution of PMG greatly varies from diffuse, symmetrical, bilateral,
asymmetrical or unilateral (Kuzniecky 2015). With the small convolutions come
underlying laminar abnormalities. Takano discusses PMG is also one of the most
common MCDs and has different types, unlayered and 4-layered. We focus on the 4layered type. In four-layered PMG, the cortex consists of a molecular layer (1st layer)
and two neuronal layers underneath (Takano 2011). In between the two neuronal
layers is an intermediate layer that contains few cells and many fibers (Takano 2011).
It has been previously reported that approximately 85% of patients diagnosed
with polymicrogyria have seizure disorders (Leventer, Guerrini et al. 2008). As
mentioned in Leventer et al. (2008), PMG is also a very common additional
component with other disorders such as chromosomal deletion syndromes, metabolic
disorders, and multiple congenital anomaly syndromes. Additionally, PMG , unlike
other MCDs has non-genetic causes that are recognized (Stouffer, Golden et al. 2015).
The incidence of epilepsy with PMG is very high (Kuzniecky, Andermann et al.
1993); the susceptibility of seizures most often peaks during brain growth and
synaptogenesis during childhood in humans, suggesting that the immature brain is the
focus for the initiation of the epilepsy (Rakhade and Jensen 2009, Takano 2011). The
seizures associated with PMG tend to be intractable in about 50% of the cases of
patients, and also tend to show up in childhood (Leventer, Guerrini et al. 2008). This is
important because seizures can be caused by different factors depending on the age of
a person (Fisher and Saul 1997). The young brain is different from the adult brain in
many ways; the young brain is not a smaller adult brain. We cannot get the
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information we need from adult brains in order to elucidate the underlying
mechanisms of developmental epilepsy (Ben Ari 2006).
In our lab, we use the freeze-lesion (FL) model due to its ability to accurately
replicate the histopathology and hyperexcitability of the microgyria associated with
seizures. We specifically look for mechanisms in development because we want to
ultimately identify the one(s) that produce the onset of this hyperexcitability.
Freeze lesion model of microgyria
PMG has been modeled by a number of insults to the neonatal cortex,
including direct ibotenic acid injection, stabbing punctures, and most commonly, a
neonatal transcranial FL. In the normal developing brain, the cortical layers form in
an inside-out progression, with the bottom layers forming first and the upper layers
following. The model used for experiments described in this dissertation is the
neonatal FL, performed on postnatal day (P) 1 in mouse. Lesions are done on P1, as
opposed to P0, because lesions at P1 are more likely to cause the chronic
hyperexcitability (Jacobs, Hwang et al. 1999). The lesion produces a focal loss of
neurons within the cortical plate at the time of the lesion. At P1 in mouse, this is some
of layer IV, and all of layers V and VI. The superficial layer neurons will migrate into
the cortical plate on subsequent days. For this model, mice are anesthetized and a
frozen probe is placed onto the skull overlying somatosensory cortex for a few
seconds, creating a focal loss of the neurons present in the cortical plate at that
developmental age (Jacobs and Prince 2005) (Figure A). Thus, this FL process
mimics a fetal stroke or direct injury resulting in focal loss of neurons. In addition, this
FL model shows epileptiform activity consistently and is therefore a useful model for
8

study of the underlying mechanisms of epileptogenesis associated with polymicrogyria
(Jacobs, Hwang et al. 1999).
It has been shown that these FL animals have intrinsic hyperexcitability in the
area adjacent to the lesion. The cortex adjacent to the microgyrus, from which the
epileptiform activity is most easily evoked is known as the paramicrogyral region or
PMR. The cellular changes that cause this increased excitation seen in this model are
unknown, however, the knowledge of these mechanisms will help provide special
Figure A. Freeze lesion model of microgyria.
A) Freeze probe diagram, modified from
Humphreys, Rosen et al. (1991). Probe was
placed in dry ice to cool methyl butane. B)
Although previous studies in rat utilized a
unilateral lesion, for these studies bilateral
lesions over somatosensory cortex were made
in mice. C) Probe placement results in focal
death of cells present in the cortical plate (deep
layers). D) Over the next 5-7 days normal
processes remove these cells. E) As a result of
lost cells a sulcus forms in the normally
lissencephalic rodent cortex. F) Normal
migration of superficial layer cells into the
cortex continues after the lesion. G) Example of
a Nissl-stained coronal section through
somatosensory cortex containing the induced
microgyrus with abnormal lamination and the
abrupt transition (gray dashed outline) to
normally laminated 6-layered cortex. This
example is from a rat. Figures C-G by KM
Jacobs.
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targets for therapeutic treatments (Andresen, Hampton et al. 2014). Though the
mechanisms are unknown, field epileptiform activity has been evoked in the PMR,
laterally adjacent to this malformation. When connections from the PMR region are
severed from the microgyrus, the hyperexcitability seen in the PMR region persists
(Jacobs and Prince 2005). Afferents avoid the microgyrus and instead, relocate to the
PMR (Rosen, Burstein et al. 2000) (Figure B); this is what leads to increased
excitatory connectivity in this area (Jacobs, Kharazia et al. 1999, Jacobs and Prince
2005). Increased excitatory afferents must be selective to certain neurons or other
components of the circuit in order to overcome the inhibition as with increased
Figure B. Thalamocortical excitatory
afferents avoid the malformed region
and project instead to the PMR. In the
cartoon at the top, the normal focal
projections can been seen. In the lower
cartoon depicting the malformed cortex,
the thalamic afferents that should have
gone to the malformed area instead find
the normal layer IV in the adjacent
(abnormal) region. This creates
additional excitatory afferents in this
PMR region. This has been
demonstrated both anatomically and
functionally. Figure by KM Jacobs.
excitation among pyramidal neurons (Jacobs, Hwang et al. 1999). Is it just excitatory
afferents causing this hyperexcitability?
Network hyperexcitability was originally identified with field potential
recordings in ex vivo slices. Nemes, et al. discussed how pro-epileptic lesions are a
predisposing factor for the development of chronic epilepsy if triggered by an event
such as ischemia or a seizure. The presence of hyperexcitability increases a patient’s
10

chance of developing epilepsy. This is why stopping the hyperexcitability before
seizures occur is key. While the network epileptiform activity begins abruptly and is
severe at P12, the functional increase in excitatory activity to layer V pyramidal
neurons begins on P9. Thus some other mechanism likely contributes to the initiation
of the epileptiform activity. This led us to look at inhibitory interneurons as the cause.
In the PMR region, there are more glutamatergic synapses to layer V
pyramidal neurons and interneurons (Jacobs & Prince, 2005). This increased
glutamatergic signaling onto certain subtypes of interneurons is important and could
affect the excitability of the PMR region (Takano 2011). In the PMR, others from our
lab have previously shown that layer V pyramidal neurons receive an increase in these
excitatory connections. The increase in excitatory synapses to excitatory neurons
occurs at P10, yet we do not see epileptiform field potentials until P12 (Figure C).
This suggests that there are likely other abnormalities involved in initiating the
epileptiform activity.
Figure C. Timing of
onset of epileptiform
activity. Activity was
recorded as field
potentials from ex vivo
rat slices. Survival age
is postnatal day. Note
that before P12 (purple
arrow) only normal
short latency events
were evoked. Figure
modified (colorized)
from Jacobs, Hwang et
al. (1999).
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Previous recordings from inhibitory cells showed that inhibitory cells of the
PMR receive nearly three times the excitation that controls have. What is the cause of
this excitation? The early susceptibility seen that does not coincide with the increased
excitation onto pyramidal neurons may be caused by inhibitory neuron changes or
changes with their connectivity (George and Jacobs 2006, George and Jacobs 2011,
Bell and Jacobs 2014). In addition, since the onset is delayed, this is an important
period of latency to study in order to determine the mechanisms of epilepsy, especially
since seizures alter many processes such as physiological processes that can worsen
hyperexcitability (Bell and Jacobs 2014).
There are a few known mechanisms that can contribute to epileptogenesis and
increased hyperexcitability in the FL model. There are thalamocortical afferents that
should have projected to malformed region that instead project to the PMR that could
contribute but not initiate the hyperexcitability. In addition, there are increased AMPA
and NMDA receptors, and decreased GABA receptors. There is increased excitatory
input to layer V pyramidal neurons which is an important contributor. Lastly, there are
GABAergic neurons decreased in number. This could be an important contributor to
network hyperexcitability. After the FL, neurons migrate from the cortical plate and
form a bridge-like structure. This structure maintains an early Cl- homeostatic
environment which causes GABA to be depolarizing, promoting the formation of this
disorganized network and also promoting the abnormal migration of neurons and
could affect the hyperexcitability seen in the PMR (Shimizu-Okabe et al., 2007). This
depolarizing effect of GABA is essential in order for neurons and interneurons to
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migrate (Wang, Kumada et al. 2012). The effect of GABA can affect not only effect
excitatory neurons, but can also effect inhibitory neurons.
1.3 Inhibitory interneuron subtypes
In the cortex, 70-80% of the neocortical neurons are excitatory pyramidal cells,
the other 20-30% are inhibitory interneurons (White 1989). There are many types of
GABAergic interneurons that are distinguishable by their morphology/axonal
arborization because certain interneurons are specialized at targeting different domains
of neurons, different cortical columns, or even different layers of a column (Markram,
Toledo-Rodriguez et al. 2004). Inhibitory neurons have certain characteristics that
make them distinguishable from pyramidal neurons such as size, soma shape, action
potential firing pattern, and laminar layer location. Interneurons can target other
interneurons with inhibitory synapses onto other cells, usually occurring at the
dendrites, just as for pyramidal neurons.
Inhibitory interneurons have many functions, they must balance the excitation
on different regions of a neuron, and only about 16% of pyramidal neuron synapses
are from inhibitory interneurons (Markram, Toledo-Rodriguez et al. 2004). At certain
inhibitory synapses there is less depression compared to excitatory synapses, allowing
some interneurons to fire at higher frequencies (Galarreta and Hestrin 1998, Wang,
Gupta et al. 2002). Inhibitory interneurons must be activated at the right moments,
they must constantly be in balance, or else the network can become faulty. Any
interruption of the normal balance can lead to disruptions in the normal functioning of
the network.
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The balance between excitation and inhibition is important when discussing
inhibitory cells because in the end, these interneurons control the synchronization at
certain frequencies (Konig, Engel et al. 1996, Markram, Toledo-Rodriguez et al.
2004). The diversity seen in inhibitory interneurons is important for the maintenance
of the brain’s connections. This regulation is important to guarantee the proper
processing of stimuli in a given brain region in an unpredictable and ever changing
environment (Markram, Toledo-Rodriguez et al. 2004).
Inhibitory interneurons can be differentiated in many different ways, including
staining methods and intrinsic firing properties (Connors and Gutnick 1990,
Kawaguchi and Kubota 1995, Kawaguchi and Kubota 1996). Among peptides in the
neocortex, vasoactive intestinal peptide (VIP) and somatostatin (SS) staining are
expressed in different GABAergic cells (Demeulemeester, Vandesande et al. 1988,
Rogers 1992, Kubota, Hattori et al. 1994, Kawaguchi and Kubota 1996). Parvalbumin
(PV) stained interneurons are immunoreactive for the calcium binding protein PV.
These three subtypes are the prominent inhibitory interneurons. SS interneurons have
different roles in the cortical circuit (Kawaguchi and Kubota 1996). SS are mostly
low-threshold spiking (LTS) neurons and PV interneurons are mostly fast-spiking (FS)
interneurons (Markram, Toledo-Rodriguez et al. 2004). FS interneurons have lower
input resistances and tend to spread horizontally and control horizontal activity
(Gonzales-Burgos, Krimer et al. 2005). SS interneurons are found in the hippocampus,
all throughout the neocortex, and tend to be more modulatory. They form synapses on
the distal dendrites of pyramidal cells and spread vertically rather than horizontally
(Kawaguchi and Kubota 1996).
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Rosen et al. (1998) demonstrated that the numbers of PV-expressing neurons
are decreased focally in deep layers, but another study that counted all GABAergic
neurons showed there was no difference. In normal cortex, PV interneurons are the
stronger inhibitory cells (Hu, Gan et al. 2014), however, in the PMR, there are fewer
PV interneurons, and they seem to no longer be the main inhibitory cells (George and
Jacobs 2011). The Jacobs’ lab has used stereology to count numbers of SS, PV and
VIP neurons. Within and surrounding the malformation, PV neuronal counts are down
while SS and in some cases VIP neuronal counts are increased. We have hypothesized
that the PV neurons are more vulnerable to the hypoxic insult while the SS neurons are
resilient. It may be that homeostatic attempts to maintain cortical inhibition allow PV
neurons and/or synapses to be replaced by SS neurons and/or synapses. This could
account for SS interneuron increased strength within the PMR. All of these data
together suggest that the interneuron subtypes are differentially affected.
GABAergic interneurons contain many mGluRs that act on then by
depolarizing them directly. The result of this is greater inhibition, wherever these
synapses are made, which is on both excitatory and inhibitory interneurons (Zhou and
Hablitz 1997). In addition, recent studies show that LTS interneurons, due to their
electrically coupled networks, are suited to modulate cortical excitability (Gibson,
Beierlein et al. 1999). LTS neurons in the PMR have been shown to have an increased
maximum frequency when compared to LTS neurons in control tissue (George and
Jacobs 2011). Additionally, a decreased firing frequency was seen in FS cells as
compared to the LTS interneurons (George and Jacobs 2011). Since the interneuron
subtypes are maintained in the PMR, this suggests that differentiation normally
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proceeds once the lesion is induced. It could also mean that the mechanisms

Figure D. Changes in cortical inhibitory subtypes after
malformation. In normal (control) cortex, the PV interneurons
project horizontally and provide a powerful suppressant of
horizontally (intercolumnar) excitatory activity. In contrast, the
SS interneurons normally project intracolumnarly and provide
weak or modulatory inhibition onto the dendrites of both
excitatory and inhibitory neurons. In malformed cortex,
specifically within the PMR, we hypothesize SS neurons are
strengthened in function. This is supported by the increased
excitatory synaptic activity they receive, the increased maximal
firing and increased output (described below) determined
optogenetically. This increased function of the inhibition may
serve to both synchronize excitatory activity within a column and
produce disinhibition due to the contacts onto PV interneurons.
Reduced functioning of PV interneurons may then allow the
spread of this synchronized excitatory activity across the cortex
in the form of epileptiform activity.
underlying cell type definition are complete in layer V prior to lesion time (George
and Jacobs 2011). The interneuronal subtypes can be affected in different ways in both
animal models and in human tissue so these interneurons are useful to study
(DeFelipe, Garcia et al. 1993, Buckmaster and Dudek 1997, Rosen, Jacobs et al. 1998,
Powell, Campbell et al. 2003, Trotter, Kapur et al. 2006). We are interested in these
interneurons because we believe that these inhibitory cells are the cause of the
epileptiform activity seen in our model. We have previously shown via whole cell
patch clamp recordings that the SS interneurons within the PMR receive more
excitatory synaptic input and fire action potentials at higher maximal rates compared
to control SS interneurons. This increased strength of these intracolumnar interneurons
may synchronize excitatory activity within a column. In addition, increased strength
from SS to other interneurons may produce network disinhibition. Since these
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interneurons project vertically, rather than horizontally like the PV interneurons, they
synapse in multiple layers simultaneously. Since these vertical SS synapses are usually
modulatory, they normally do not create robust synchrony. It has also been shown that
in the presence of mGluRs, SS interneurons fire in an oscillatory manner and that
activity can cause an increase in synchrony among the nearby pyramidal neurons
(Connors and Gutnick 1990). It is the combination of these two normal processes
(intracolumnar projection and synapses onto other inhibitory interneurons) with the
strengthening of their function in the PMR that has led us to hypothesize that the PMR
has an increase in intracolumnar synchrony. Overall, we hypothesize that PV
interneurons that are normally strong become weakened in the PMR, while SS
interneurons that are normally weak or modulatory become strengthened in the PMR
(Figure D).
There are two ways SS interneurons may be producing network excitation with
their inhibitory synapses. They synapse onto the PV interneurons, and since they are
inhibitory cells, we hypothesize more strongly in the PMR, they inhibit these
inhibitory cells, which could lead to excitation. Secondly, since SS interneurons
project vertically, they cause the synchronous inhibition and firing of pyramidal
neurons. Normally, the SS interneurons are not powerful, but if they become very
powerful, they can act to synchronize all activity, providing a jump start to
epileptiform activity. It is important to localize the cause of this increased excitation to
be able to better target neuronal and receptor subtypes for drug development (Jacobs,
Hwang et al. 1999). What about these SS interneurons makes them more powerful in
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the PMR? While previous studies have looked at inputs to these neurons, this project
looks at the output from these specific subtypes utilizing optogenetics.
1.4 Controlling inhibitory interneuron subtypes selectively
Optogenetics is optical methods combined with genetic methods in order to
achieve gain or loss of function of certain events on specific cells in living tissue
(Deisseroth 2011). Optogenetics allows for targetable control tools that do three
things: deliver effector function, respond to light, and enable technology for: 1)
targeting the control tools in cells of interest; 2) electrical recording of evoked activity
or other analysis; and 3) delivering light into the tissue that is under investigation
(Deisseroth 2011). Neurons can be specifically controlled when they express proteins
that are sensitive to light (LaLumiere 2011). Fenno et al. (2011) mentions that with
this technology, we have been able to selectively mark SS interneurons with
Channelrhodopsin (ChR), enabling us to activate these specific interneurons with blue
light. Type I rhodopsin combines light sensation and ion flux into one protein
encoded by one gene (Fenno, Yizhar, & Deisseroth, 2011). Fenno et al. (2011) states
that with light stimulation, the channel changes conformation and opens. In the
absence of further light stimulation, it changes back to the closed conformation.
Transgenic mice, as opposed to viral transfection of ChR, allow for greater control
over transgene expression because of the use of large promoter fragments (Fenno,
Yizhar, & Deisseroth, 2011). The optogenetic system dependent on Cre allows for a
direct look at the neural activity of specific neuronal populations and their relationship
with animal behavior (Fenno, Yizhar et al. 2011). In order to achieve the ChR
expression on SS interneurons, we crossed Floxed stop codon on a ChR-2 expressing
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gene in YFP reporter female mice with Cre recombinase in the 3' UTR of the
somatostatin locus males. This allowed for the selective activation of the SS
interneurons with blue light. We have recently shown with optogenetics that SS
interneurons of the PMR produce more output than the same interneuron subtype in
control (Figure E). We have also shown that epileptiform fields can be generated with
light activation of SS interneurons alone (Figure F). This suggests that reducing the
activity of SS interneurons may be an effective way to prevent epileptiform activity
associated with microgyria. We can achieve this via control of metabotropic glutamate
receptors. This is beneficial because the effectiveness of therapy is limited in about
30% of all epilepsy cases, and these mGluRs are very good targets (Loscher, Dekundy
et al. 2006).

Figure E. IPSC produced by selective, optogenetic activation of SS interneurons.
After mating Cre-SS mice with floxed-ChR mice, ChR is present selectively in SS
interneurons (although there may be ~10% error (Hu, Cavendish et al. 2013)). Whole
cell patch clamp recordings were made in layer V pyramidal neurons. Blue light
(bLED) was applied through the 60X objective above the recorded neuron to activate
the ChR in SS interneurons. Data shown is from the work of Nicole Ekanem in the
Jacobs lab. A preliminary form of this data was published in the Masters’ thesis of
Ekanem (2015). This data will serve as the untreated form to which the studies
presented in the current Masters’ thesis will be compared.
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Figure F. ChR-SS evoked epileptiform field potentials from ex vivo slices
containing an induced microgyrus. At the arrow a 2 msec long pulse of blue light
was applied through the 60X objective centered on layer V within the PMR (~0.25
mm adjacent to the sulcus) in order to activate the ChR selectively genetically
inserted in SS interneurons. Field potential recordings were made within layer V in
the center of the applied light. The aCSF bath contained a low level (0.02 mM) of
the GABAA receptor antagonist, Gabazine, in order to increase network excitability.
This epileptiform field was not obtained from control slices under the same
conditions, suggesting that only within the malformed cortex can activation of
inhibitory interneurons produce this network hyperexcitation. These data collected
by Weston, Ekanem and Jacobs and originally published as part of Nicole Ekanem’s
Masters’ thesis (2015).

The mGluRs are members of the G-protein coupled receptor super family
(GPCRs) (Jong, Sergin et al. 2014). GPCRs are the largest members of membrane
proteins; they also mediate a variety of cellular processes (Rosenbaum, Rasmussen et
al. 2009). They are characterized by having seven helical membrane spanning regions
(Rosenbaum, Rasmussen et al. 2009) and can interact with many second messengers.
They can also be hindered by many different proteins. On the cell surface, mGluRs
have GPCR independent signaling through β-arrestin and GPCR dependent signaling
(Jong et al., 2014). β-arrestin blocks the receptor/G-protein interaction. This is an
adapter protein that targets GPCRs for clathrin mediated endocytosis (Luttrell and
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Lefkowitz 2002). The three main functions of β-arrestin are to aid in GPCR coupling
efficiency, to sequester GPCRs, and to downregulate/re-sensitize GPCRs (Luttrell and
Lefkowitz 2002). It can also recruit signaling proteins to GPCRs that are agonist
occupied (Luttrell and Lefkowitz 2002). The mGluRs can act through phospholipase C
(PLC) or adenylate cyclase (AC) by coupling with GPCRs directly to ion channels or
to second messenger cascades (Szydlowska, Kaminska et al. 2007).
There are 8 different groups of mGluRs that are classified into three groups
based on homology, pharmacological profile, and coupling to intracellular pathways
(Lujan, Shigemoto et al. 2005). The three 3 different subgroups of mGluRs are named
after their agonists.
Group I mGluR modulates the inhibitory interneurons. Group I is made of
homomeric receptors containing either subunit 1 or subunit 5 and are thus referred to
as mGluR5 and mGluR1. Most agonists are not selective for mGluR1 or mGluR5, but
there are very good antagonists that are selective. My thesis focuses on these Group I
mGluRs, which are excitatory postsynaptic receptors (Jong, Sergin et al. 2014). Group
I mGluRs are proconvulsive by increasing membrane excitability and are excitatory
receptors that enhance neurotransmitter release, regulate inhibitory glutamate
receptors (iGluR) responses, and control many depolarizing currents (Alexander &
Godwin, 2006). Group I mGluRs are modulatory and act slowly via their G-protein
and second messenger involvement (Alexander & Godwin, 2006). In addition, they
are positioned in many areas that are only active under high neuronal activity
conditions. The mGluR1 and mGluR5 null mice show no seizure behaviors
(Alexander and Godwin 2006).
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The mGluR5 are prominent in areas involved with emotion, motivation,
learning, and memory, and also play a large role in many disorders and diseases,
including epilepsy (Jong, Sergin et al. 2014). This receptor is a great target because it
has been shown to be necessary for induction of epileptiform activity (Wong, Bianchi
et al. 2005). As mentioned in Jong et al. (2014), it acts through Gq/11 and regulates
cell function via transcriptional profile changes and modulating translation of dendritic
mRNAs. It also has an orthosteric binding site on its cytosine rich domain and has
allosteric binding sites that when bound by drug, decrease the activity of the main site
or can have a neutral effect. Unlike mGluR1, mGluR5 does not experience ligand bias.
Ligand bias refers to when a ligand keeps a unique conformation that triggers either a
G-protein dependent or independent pathway. Intracellular signaling is present and is
thought to be through the actions of β-arrestin. Intracellular signaling has been shown
to be an evolutionarily conserved feature and has been shown in C. elegans and plants,
suggesting that it must play some important role. Intracellular GPCRs can regulate
many functions such as inflammatory responses, proliferation, and survival. For
intracellular GPCRs, there are two uptake systems: through Na+ dependent excitatory
AA (amino acid) transporters or via a cystine/glutamate exchanger (Jong, Sergin et al.
2014).
The mGluRs that are present in the postsynaptic membrane tend to mediate
membrane properties via second messenger interactions, and when they are present on
the presynaptic terminal, they aid in synaptic vesicle release (Alexander & Godwin,
2006). Targeting this mGluR5 receptor could control glutamatergic signaling due to its
modulatory functions for ongoing activity without interfering with the functioning of
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ionotropic glutamate receptors (iGluRs) (Alexander & Godwin, 2006). It is thought
that Group I mGluRs are unattractive targets because mice with a null mutation for
mGluR1 or mGluR5 showed a disruption in cerebellar motor function and long term
potentiation (LTP) (Alexander and Godwin 2006). These observations, however, were
observed in normal, non FL animals. Previous work in our lab has shown the mGluR5
is enhanced in its expression and in its activity in the PMR region in our FL model
relative to its expression and function in control cortex (Figure 1.43A).

Figure G. Expression of mGluR5 is increased within PMR compared to control
cortex at both P16 and P2. Left panel: Example Western Blot data for mGluR5
(subsequently normalized to b-Actin) for the PMR (1 mm circle of tissue through
cortex taken ~0.5 to 1.5 mm lateral to the sulcus, in homologous control cortex, at ~
2.5 to 3.5 mm lateral to the sulcus (Lesion far) and in homologous control cortex.
Right panel: Expression was quantified by digital measurement of the intensity from
film exposed to the radioactive blots (NIH’s Image program). * = t-test, p< 0.05.
In previous lab studies, antagonists targeting this receptor have been shown to
affect LTS but not FS cells when recordings were taken in ex vivo slices in normal
cortex. In the PMR, LTS neurons respond more to DHPG, a Group I mGluR agonist,
than control neurons did (Figure H). In addition, the response to DHPG is only via the
mGluR1 receptor in control, but the response in PMR is both mGluR1 and mGluR5.
Targeting of the mGluR5 receptor will therefore be less likely to interfere with the
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normal functioning tissue and hopefully only target the abnormal areas. We believe
that the enhancement of this receptor on SS interneurons is the cause of the
epileptiform activity seen in the FL model. We hypothesize that blocking these
mGluR5 receptors will lead to a decrease in the excitation seen in the PMR region of
our FL animals by decreasing the output of these SS interneurons. Not only do we
hypothesize that this will inhibit the epileptiform activity, but we hypothesize that it
will aid in other developmental disorders that have epilepsy as a co-morbidity. Since it
has been shown that mGluR5 is increased in expression as early as P2 (Figure G),
early treatment is suggested. To test this hypothesis, Gabapentin (GBP), a current
antiepileptic drug (AED), and MTEP, an mGluR5 antagonist, will be used on PMR
and control animals.
Figure H. Effect of local application of mGluR1/mGluR5
agonist DHPG (0.01 mM) on IPSCs recorded in layer V
pyramidal neurons of control (yellow) and PMR (purple)
cortex. In control neurons, DHPG cause nearly a doubling
in the frequency of IPSCs, while in the PMR it caused more
than a tripling of the IPSC frequency. Numbers of recorded
neurons shown lower part of the bars. * = t-test, p< 0.05. In
additional experiments it was demonstrated that bath
application of an mGluR1 antagonist prevented the
increased IPSC frequency associated with local DHPG in
controls but not in the PMR. Under these conditions, bath
application of an mGluR5 antagonist eliminated the
increase in the PMR. Work from George and Jacobs.
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1.5 Potential treatments for malformation-associated epileptiform activity
GBP will be used to test whether it can block the early development of
epileptiform activity, as well as whether it changes the increased output from SS
neurons. It is a current anticonvulsant that has structural analogy to GABA (Kim,
Chang et al. 2009). It can be administered at therapeutic doses, unlike other AEDs that
have to be slowly introduced into the system (R. Fisher & Saul, 1997). GBP has a lack
of drug interaction, is cleared by the kidney, and exhibits minor side effects compared
to most anticonvulsants (R. Fisher & Saul, 1997). In addition, GBP has not been
shown to have any long term effects during development (Martin, McClelland et al.
2002). On the other hand, it does have a short-half life and is mainly used as an add-on
medication to other anti-seizure medications (Fisher and Saul 1997). GBP blocks the
influx of calcium into neurons (Traa, Mulholland et al. 2008 ) by blocking the
interaction of TSP and α2δ-1, a calcium channel subunit (Figure I). This is the
receptor for TSP mediated synaptogenesis (Eroglu, Allen et al. 2009, Andresen,
Hampton et al. 2014). TSP 1/2 is expressed during the postnatal period when many
excitatory synapses are forming. TSP is not present in the adult brain when excitatory
synapses are greatly reduced (Eroglu, Allen et al. 2009). α2δ-1 is an accessory subunit
of voltage gated calcium channels and aids in membrane trafficking (Andresen,
Hampton et al. 2014), affects the voltage dependence of activation, and also affects the
increase in current amplitude activation and inactivation kinetics (Arikkath and
Campbell 2003). These channels can also influence other channels (Andresen,
Hampton et al. 2014). GBP inhibits voltage gated calcium channel (VGCC) trafficking
and directly inhibits calcium currents, this causes GBP to exert inhibitory effects on
intracellular α2δ subunits (Hendrich, Tran Van Minh et al. 2008). All in all, α2δ-1
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mediates important functions physiologically and the loss of this subunit can have
severe consequences on functions relying on calcium channel trafficking and calcium
currents (Arikkath and Campbell 2003). As mentioned in Andresen et al. (2014), this
subunit’s role in synaptogenesis, however, is independent of the calcium channel.
Treatment with GBP for inflammation such as in multiple sclerosis prevents injuryinduced excitation as well as a decrease in the amount of reactive astrocytes. It also
decreased excitatory input onto layer V pyramidal neurons when used as a treatment in
the FL model. GBP seems to eradicate most of the pathologies that are associated with
the FL model, such as hyperexcitability, both in vivo and in vitro (Andresen, Hampton
et al. 2014). Even though GBP prevents formation of excitatory synapses in vitro and

Figure I. Gabapentin blocks the interaction of thrombospondin and a2d-1 calcium
channel subunit, thereby preventing excitatory synapse formation. Figure from Stahl, S.
et al. (2013).
in vivo, it does not affect already formed synapses; since there is a treatment window
of 1 week that it is effective (Eroglu, Allen et al. 2009). It is unknown at this point
whether GBP affects interneuron function.
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When mGluR5 is expression is enhanced, an antagonist could be used (Wong,
Bianchi et al. 2005) to reduce activity to normal levels. This is why we chose to test
MTEP, an mGluR5 antagonist as a potential treatment for the epileptiform activity
occurring in the PMR. The mGluR5 produce effects through a number of intracellular
signaling pathways (Figure J). The mGlu5 receptors play a role in proper
development, because if it is knocked out, barrels do not form due to interruption of
the mGlu5 signaling through PLC-β1 (Hannan, Blakemore et al. 2001). A barrel is a
specific anatomical unit in layer IV that represents an individual whisker (Woolsey
and van der Loos 1970). These barrels make up a somatotopic map in the primary
somatosensory cortex (Petersen 2007). Barrels allow for the delineation of functional
organization, plasticity, and development (Petersen 2007). When sensory information
is received, it is processed within the barrels depending on the whisker-related
behavior (Petersen 2007). As previously stated, our model shows an excess of the
mGluR5 receptor in PMR tissue as early as P2. There are other mGluR5 antagonists,
such as MPEP that have been previously used. We chose MTEP over MPEP because
MTEP has been shown to have a greater selectivity for the mGluR5 receptor and is
also more highly selective for mGluR5 without having effects on other mGluR
subtypes as compared to MPEP (Colmers, Lukowiak et al. 1987, Lea, Movsesyan et
al. 2005, Domin, Kajta et al. 2006, Lea and Faden 2006). Additionally, MTEP has
shown to be more potent in vitro and in vivo (Szydlowska, Kaminska et al. 2007).
MPEP has been shown in rodents and in Xenopus laevis oocytes expressing rat AMPA
receptors to affect both AMPA and NMDA receptors (Gasparini, Lingenhohl et al.
1999, Olive, McGeehan et al. 2005, Lea and Faden 2006). MPEP has also been known

27

to have electrophysiological effects on subtypes of NMDA receptors and kainate
receptors (Lea and Faden 2006). MTEP has been shown to be effective at low doses
and also does not have an effect on NMDA receptors, AMPA receptors, or kainate
receptors (Cosford, Tehrani et al. 2003, Slassi, Isaac et al. 2005, Lea and Faden 2006,
Loscher, Dekundy et al. 2006, Nagal, Greco et al. 2015). In addition, as discussed in
Nagal et al., MTEP has a higher potency in human cloned receptors as compared to
MPEP. It has also been shown to penetrate the blood brain barrier well. At
behaviorally active doses, MTEP produces complete occupancy of the mGluR5
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receptor, and based on in vitro affinity, also produces brain free concentrations high
enough to occupy the receptor (Nagal, Greco et al. 2015). Together these data suggest
that blockade of mGluR5 receptors may be an effective means to reducing
epileptiform activity associated with microgyria. We expect that chronic blockade will
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have no effect on interneurons in controls, because these receptors are not active on
controls. Therefore treatment should be selective on extra function in PMR.
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Chapter 2
Potential Treatments for Malformation Associated Epilepsy
2.1: Hypothesis and Objectives
Polymicrogyria, a developmental cortical malformation, can cause intractable
epileptic seizures in affected individuals. This disorder has a lack of therapeutic
treatments and drives a need to determine the underlying cellular mechanisms of cortical
malformations also causing intractable seizures.
These studies utilize a freeze-lesion model for polymicrogyria in transgenic mice
that selectively express ChR channels on a particular interneuron cell type. These cells,
within an epileptogenic area adjacent to the malformation known as the paramicrogyral
region, are thought to be functionally altered as compared to control cortex, and have
been shown to contribute to the epileptiform activity seen in the PMR/FL mice. Past
studies have implicated the mGluR5 receptor as the cause of the over activation of these
SS interneurons. This mGluR5 receptor is enhanced in its expression on SS interneurons
in the PMR region, but not in control tissue.
We hypothesize that blockade of the mGluRs will decrease the activity of SS
interneurons and thereby prevent the generation of epileptiform activity and increased SS
output in malformed cortex. With the following series of experiments, we assessed this
by:
1. Evaluating if the drug-treated mice (GBP or MTEP) showed suppressed
epileptiform fields in drug-treated PMR vs drug-treated sham-lesioned control
animals.
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2. Evaluating the output of the SS interneurons in our 4 treatment groups
(control-GBP, PMR-GBP, control-MTEP, PMR-MTEP) via whole cell patch
clamping of pyramidal neurons with the use of optogenetics.
All recordings were taken from pyramidal neurons in the designated PMR region
or homologous control cortex.
2.2: Materials and Methods
Mice
In order to achieve the ChR expression on SS interneurons, we crossed Floxed
stop codon on a ChR-2 expressing gene in YFP reporter female mice with Cre
recombinase in the 3' UTR of the somatostatin locus males. This allowed for the selective
genetic insertion of ChR into SS interneurons, subsequently allowing activation of the SS
interneurons with blue light application. Mice are housed in IACUC approved housing
and all procedures and protocols are IACUC approved.
FL surgery
On postnatal day 1, aseptic surgery techniques were followed to induce the
transcranial freeze lesions. SS-ChR2-EYFP mice were anesthetized by being placed in
ice for 3 minutes to induce hypothermia. A coronal incision was made across the skull to
expose it. A frozen probe consisting of a copper bar with a 0.1mm pointed tip cooled with
dry ice to -55˚C was placed on the surface of the skull for 5 seconds on each hemisphere
(bilateral lesion) approximately 0.5 mm from the midline. After surgery, the incision was
sutured on the center and Vetbond glue was applied to the rest of the incision. Antibiotic
ointment was then applied to the whole suture and the mice were then placed in a heating
blanket and allowed to re-warm to normal body temperature. Pups were then returned to
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their mother. The pups were weighed for five days following the surgery to ensure they
gained weight and therefore had a proper recovery.

SHAM surgery
This surgery comprised of the same series of events as the FL surgery, however,
instead of the freezing probe cooled to -55˚C, the probe was room temperature.
Drug administration
Freeze-lesioned and control (sham-lesioned) mice were all given one of two
drugs, MTEP or Gabapentin. From postnatal day 1 through postnatal day 7 (P1-P7), the
MTEP groups were given daily i.p. injections (at the same time each day) at a
concentration of 10 mg/kg MTEP. For the GBP groups, the same protocol was followed
(daily i.p. injections from P1-P7) at a concentration of 200 mg/kg. Because only a small
volume can be injected into mice pups, for drug injections, the volume was held constant
(within a small range) while the mg/ml of the drugs were varied according to animal
weight. For MTEP a volume of 0.02 mls was used. Due to the lower solubility of GBP, it
was necessary to vary this from 0.02 ml for P1-3, 0.03 for P3-5; and 0.04 for P5-7.
Brain extraction and slice preparations
Mice were anesthetized with isoflurane in a small chamber. Once overdosed, they
were decapitated. After decapitation, the brain was excised and quickly removed and
placed into cold (-18˚C) sucrose slicing solution containing (in mM): (2.5 KCl, 1.25
NaH PO , 10 MgCl , 0.5 CaCl , 26 NaHCO , 234 sucrose, 11 glucose). The brain was then
2

4

2

2

3

transferred to a flat surface and sliced mid-sagittally. One side of the brain was frozen
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and stored in a -80˚C freezer to save for later determination of mGluR5 protein levels in
the brain tissue using Western blot techniques. The other half was placed on the
vibratome stage and 300 µm coronal slices from the somatosensory cortex were taken
using a 1000 plus vibratome. Slicing occurred while the brain was in the sucrose slicing
solution. Somatosensory cortex was confirmed by using hippocampal morphology

Figure K. Images from the
Allen Brain atlas showing the
location of primary
somatosensory cortex (dark
green, arrows). Website: ©
2015 Allen Institute for Brain
Science. Allen Mouse Brain
Atlas [Internet]. Available
from: http://mouse.brainmap.org. Because there is far
less somatosensory cortex
present in sections with
ventral hippocampus, only
slices anterior to this level
(equivalent to top and middle
image) were used for both
field potential and patch
clamp recordings.
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(Figure K). After slicing, the slices were transferred to a warmed holding chamber filled
with artificial cerebral spinal fluid (aCSF) infused with 95% O2/5% CO2 to maintain pH.
ACSF is comprised of (mM): 126 NaCl, 3.5 KCl, 1.25 NaH PO , 1.0 MgSO , 1.2 CaCl ,10
2

4

4

2

glucose, and 26 NaHCO . Slices remained in the heated chamber of 34˚C for 25 minutes,
3

after which the heater was turned off and the slices cool to room temperature over 20-30
minutes. Slices were kept at room temperature until used for the patch and field
recordings.
Patching and Field recordings
Before recording, the slices were transferred from the room temperature bath into
the recording chamber with continuously flowing aCSF (~300 mOsm) infused with 95%
O /5% CO that was heated to 32˚C. In all instances, the aCSF contained 50 μM 2-amino2

2

5-phosphonopen- tanoic acid (APV), an NMDA antagonist, and 20 μM 6,7Dinitroquinoxaline-2,3-dione (DNQX), an AMPA and kainate antagonist. A high
chloride intracellular solution was used (in mM: 70 K-gluconate, 10 Hepes, 4.0 EGTA,
70 KCl, 4.0 Na- ATP, and 0.2 Na-GTP) in the glass pipette for the pyramidal recordings
(~3-5 mOhms). Osmolarities and pH of both intracellular solutions were adjusted to 280290 mOsm and pH 7.3. Biocytin (0.5%) was included in recording pipettes to confirm
neuronal morphology post-experiment via subsequent staining (25mg of biocytin was put
into 5mL of high Cl- solution).
In malformed cortex, the sulcus could be easily visualized under standard DIC
optics. In these slices recording locations were chosen within the PMR, 0.25 – 0.5 mm
adjacent to the sulcus or for controls, in homologous cortex (see Figure 1). In all cases
the recording location was within somatosensory cortex.
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In the patch clamping experiments, an electrical stimulus was applied 100-150 μm
lateral to the patched cell using a glass pipette filled with 1 M NaCl. Optical stimulation
of the pyramidal cells was achieved using X-cite and XLED1 software (Lumen
Dynamics) with the light applied through the 60X objective. To activate ChR expressing
SS interneurons, a wavelength of 460 nm was used at an intensity of 100% (Figure L).
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These wavelengths were applied through a 60X objective either above the patched cell or
100-150 μm lateral to the patched cell above the stimulating electrode, which was a
second condition recorded. MultiClamp 700B Amplifier (Molecular devices) was used
and the signal was digitized with pClamp software and a Digidata1440A (Axon CNS
Molecular devices).
For field potentials not requiring optical stimulation, the recording electrode was
filled with either aCSF or 1 M NaCl. In these experiments, a stimulating electrode was
placed in layer V and a recording electrode was placed in layer II/III. An ER1 amplifier
(Cygnus Technologies) was used and the signal was digitized with pClamp software and
a Digidata 1322A (Molecular Devices).
Protocols
Utilized protocols were as follows: (1) A series of increasing light durations in
milliseconds (0.1, 0.2, 0.3, 0.4, 0.5, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2) was applied to determine
the effectiveness of SS interneurons in producing IPSCs within the recorded pyramidal
neuron with blue light alone. The series was repeated for a total of 3 presentations. The
responses were averaged across the 3 presentations prior to measuring amplitude,
duration, and area of the light-evoked inhibitory postsynaptic current (IPSC). Finally in
cells, (2) the recording was switched from voltage clamp to current clamp mode and a
series of hyperpolarizing and depolarizing steps applied (400 msec duration, beginning at
-200 pA and stepping at 10 pA for a total of 70 steps), in order to measure intrinsic and
cellular properties, and confirm the electrophysiological cell type.
Field potential recordings were made in layers II/III, directly above an electrical
stimulating electrode located in deep layers. Care was taken to make sure that recording
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and stimulating electrodes were vertically aligned and perpendicular to a tangent at the
pia above the recording site. Threshold current level in these experiments was that
evoking a short latency negative field of 0.2 mV peak amplitude with an electrical
stimulus of 0.02 msec duration. (3) An Epitest at half-threshold (10 sec between stimulus
presentations) was then run to test the incidence of epileptiform activity, 10 stimulus
presentations at half-threshold current were given. (4) Then, an Epitest exactly as that
described above, except at threshold intensity was run. (5) An intensity series was applied
by maintaining the current while varying the duration of the electrical stimulus (0.02,
0.04, 0.08, 0.16, 0.32 msec), with the series repeated three times. (6) Lastly, a paired
pulse stimulation was applied with paired electrical stimulations at varying durations of
electrical stimulation (0.02, 0.04, 0.08, 0.16, 0.32 msec). Because slice health varies, for
field potential recordings in order to be included for analysis, the slice had to meet three
criteria: a) A threshold current of 10 mA or less; b) an increasing peak amplitude of the
short latency field negativity with increasing stimulus intensity; and c) at maximum
stimulus intensity, the short latency field negativity must have a peak amplitude of at
least 0.6 mV. Over many years the Jacobs’ lab has found these to be reliable criteria for
detecting slice health. For patch clamp experiments, mostly the visual appearance of the
neurons was used as an indicator of health, where unhealthy slices had many cells with
swollen soma, nuclei positioned to the side of the slice and unclear membrane borders. It
is not possible to obtain patch clamp recordings from this type of unhealthy neurons, thus
other criteria thus far have been unnecessary.
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Immunohistochemistry
Field potential and patch clamp slices were immediately placed in 4%
paraformaldehyde for 24 hours after recording. After this 24 hour period, slices were
placed in phosphate buffer saline (PBS) until staining. Whole-cell patch clamp slices with
biocytin-filled cells were stained with Avidin (1:500 Texas Red conjugate, Life
Technologies) or with Avidin and NeuN (mouse anti-NeuN conjugated with Alexa Fluor
488, Chemicon MAB377X). Images of the stained pyramidal cells were taken with the
Zeiss LSM 710 confocal laser scanning microscope. Microscopy was performed at the
VCU Microscopy Facility, supported, in part, by funding from NIH-NCI Cancer Center
Support Grant P30 CA016059. Images of the slices stained with Avidin and NeuN were
obtained with the Scope A1 microscope (Zeiss) and Image Pro Premiere 9.1 (Media
Cybernetics).
Data analysis
Data was analyzed using Clampfit (Axon Instruments) and home-written macros
in Microsoft Excel. Data are presented as mean ±SEM. Statistical analysis was performed
with two-way repeated measures ANOVAs SPSS software (IBM), for measures across
intensity series and with z-tests for measures of proportion. For the 2-way ANOVAs,
stimulus intensity was the repeated measure, and subject group was the second measure.
In all cases, significance was set to p<0.05. Throughout the results the current data is
compared to that from untreated animals (both naïve controls and PMR). In all cases all
data from untreated animals was collected by Nicole Ekanem and Laura Reed and was
presented in a preliminary form in the Masters’ thesis of Nicole Ekanem (2015).
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Chapter 3
Results
3.1 Freeze-lesion histopathology not changed by drug administration
To determine whether the application of drugs altered the cortical lamination
of either control or the histopathology of the PMR, slices were
immunohistochemically stained for NeuN. Slices were chosen that contained anterior
to approximately mid-way through the dorsal hippocampus, as these slices contained
the most primary somatosensory cortex (top two pictures in Figure K). After treatment
with either MTEP or GBP, the cortical lamination was similar to that in sections from
untreated mice, as shown in Figure 1. In control, sham-lesioned mice, the normal six

Figure 1. Lamination within somatosensory cortex for both malformed (A-C)
and control brains (D-F), identified with NeuN staining. In each case the red
outlined box shows approximate recording location, with layers indicated. For
malformed brains, location is within the PMR, 0.25 – 0.5 mm adjacent to the
sulcus. A) Non-drug FL; B) MTEP FL; C) GBP FL; D) non-drug naïve control;
E) MTEP sham; F) GBP sham. Scale bar in F for A-F = 0.2 mm.
layers of neocortex were visible in sections through somatosensory cortex (Figure 1
D-F). In freeze-lesioned mice, sections showed the abnormally-laminated microgyrus
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and adjacent six-layered PMR region within somatosensory cortex. Treatment with
either MTEP or GBP did not qualitatively change the histopathology nor the
cytoarchitecture of the adjacent, six-layered PMR region from which recordings were
made (Figure 1 A-C).
3.2 Network activity measured with field potential recordings
To determine if the treatments with either MTEP or GBP affected the network
excitability, field potential recordings were made from layer II/III during stimulation of
deep layers directly beneath the recording site within somatosensory cortex and the PMR
(~0.5 mm adjacent to the sulcus). Under these conditions threshold level is determined by
adjusting the current level applied with a 0.02 msec pulse until a short latency negativity
of 0.2 mV peak amplitude is obtained. A test for epileptiform activity was then performed
by presenting 10 stimuli (10 sec interval) at half-threshold and subsequently repeating this
at threshold. While an objective quantifiable epileptiform detection system is desirable and
under development in the Jacobs lab, it was not available to assess these data. Instead, the
expertise of the lab PI (KM Jacobs) was used to identify the presence of epileptiform
activity, which has the following characteristics: 1) all-or-none behavior (that is, it is not
graded with stimulus intensity); 2) variable form; 3) variable latency; 4) typically long
latency relative to that of the short latency response which does vary with stimulus
intensity. Only polyphasic deflections at least 2 x the baseline noise were identified as
epileptiform events (Figure 2). Ictal (seizure) –like activity has a large slope and short time
to peak, extremely short peak and often repeated instances of these ictal ‘spikes’. In
contrast, interictal-like activity is typically lower in amplitude with a much more slowly
rising peak, a longer duration peak, and greater presence of polyphasic activity. For all
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subject groups studied here, in most cases the epileptiform activity observed was interictallike, although there were a few instances of ictal-like activity (Figure 2 C, I). In the

Figure 2. Examples of epileptiform activity evoked with low stimulus intensity for
different subject groups. Small blue arrows indicate time of stimulation. In all
cases the black trace is an example of epileptiform activity; and the thinner gray
trace shows a non-epileptiform response to the same stimulus presentation (from
the same file). This demonstrates the all-or-none behavior of the epileptiform
activity. A, B) Non-drug-treated controls from two different animals (A and B).
Some epileptiform activity in controls is normal for this age group (P12-21 in
rodent). C, D) Non-drug-treated PMR responses were typically larger than those
observed in controls. C and D from two different animals. E) MTEP-treated sham
control. F) MTEP-treated PMR. For all responses from MTEP-treated mice,
epileptiform activity was qualitatively similar to that in un-treated controls. G)
GBP-treated sham control. H, I) GBP-treated PMR. Ictal-like activity was
observed only in non-drug-treated PMR (C) and in GBP-treated PMR (I). Vertical
scale bar = 0.15 for A-H; and 0.45 for I.
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counting of instances of epileptiform activity, both ictal-like and interictal-like were
counted as epileptiform activity.
In untreated mice, even controls within the age group tested (P21-21) normally
have some hyperexcitability (Luhmann and Prince 1990). However in untreated
freeze-lesions, the incidence of epileptiform activity is much higher within the PMR
than in homotopic regions of control cortex, whether measured per mice or per slice
(Figure 3). Surprisingly, controls treated with MTEP had a high rate of epileptiform
activity incidence, similar to untreated PMR mice. The epileptiform incidence per
slice from PMR mice treated with MTEP was significantly lower than that for slices
from the control-MTEP-treated mice (Figure 3B, z-test, p<0.05). In addition, the
epileptiform incidence per slice was significantly lower for PMR-MTEP compared to
that in the PMR-untreated group (one-tailed z-test, p<0.05; with two tails, p =0.08).
Here a one-tailed test was applied because of the expectation that the treatment would
reduce the epileptiform incidence.
For treatment with GBP, incidence of epileptiform activity per slice was
similar to that in slices from untreated mice. That is, control-GBP was similar to
untreated controls and PMR-GBP was similar to untreated PMR. Like their untreated
counterparts, for GBP-treated mice the epileptiform incidence per slice was
significantly higher for PMR compared to control mice (z-test, p<0.05).
When epi incidence was examined per mouse, although the bars appear higher
for all drug-treated animals, the incidence was not significantly different from
untreated controls (z-tests, p>0.05), likely due though to low subject numbers. In
future experiments, we expect to obtain at least 9 mice per group.
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Figure 3. Incidence of evoked
epileptiform activity recorded
from field potentials in ex vivo
slices and analyzed both per
mice (A) and per slice (B).
Subject group is indicated
under each bar. The number of
either mice (A) or slices (B) is
shown in the bar for each
subject group. * = z-test,
p<0.05. To truly evaluate the
per mice results, likely
additional subjects must be
investigated.
3.3 Pyramidal neuron identification/differentiation
Neuronal morphology
To choose the neurons from which recordings would be made, the patch
electrode was first directed to layer V under low power. It was expected (and
subsequently confirmed) that layer V would make up the 3 rd quadrant deep to the pia.
Under high power and DIC optics, the desired pyramidal neurons were identified
morphologically as the ones having large soma; but were most easily distinguished by
the large apical dendrite that extended to superficial layers. No other cell types has this
apical dendrite. These morphological characteristics were confirmed for some neurons
with post-hoc avidin staining of the biocytin that had diffused into the cell via the
patch pipette, during the recording (Figure 4). It is possible that FL and/or drugtreatment will change detailed characteristics of the pyramidal neuron morphology
such as branch length or number. However the main characteristic of the apical
dendrite was confirmed for at least some neurons in all subject groups (Figure 4).
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Figure 4. Confirmation of pyramidal neuronal type for recorded neurons. Biocytin
was included in the recording pipette and its presence subsequently identified in the
fixed tissue with the application of a fluorescent avidin to which the biocytin binds.
Here the large somal size and presence of an apical dendrite (indicated with pink
arrows) projecting toward the pia (yellow arrow) indicate that these are pyramidal
neurons. Not every recorded neuron can be labeled, but these examples indicate that
the neurons targeted in the live slice were correct. Images were taken as maximum
projections after a depth profile on a Zeiss confocal microscope. A) Non-drug
control; B) GBP-FL; C) Non-drug FL; D) GBP-sham control. Scale bar in D for A-D
= 0.02 mm.

3.4 Optogenetic activation of IPSCs from tissue containing ChR in SS interneurons
When blue light was applied via an LED (bLED) through the 60X objective, in
tissue containing ChR in SS interneurons, IPSCs were evoked in pyramidal neurons
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(Figure 5). Responses were evoked at a relatively short latency and in a graded fashion.
That is, increasing the duration of the light to produce a more intense stimulus caused an
increase in the peak amplitude of the IPSCs for all subject groups (shown for MTEP- and
GBP-treated animals in Figure 5). IPSCs were qualitatively similar between all subject
groups.

Figure 5. Examples of IPSCs evoked by the application of blue light (bLED) in tissue
with ChR in SS interneurons. Recordings are from pyramidal neurons during
activation of SS inhibitory interneurons. A) Sham-injured mouse treated with MTEP;
B) FL mouse treated with MTEP, with recordings made within the PMR; C) Shaminjured mouse treated with GBP; D) FL mouse treated with GBP, with recordings
made within the PMR. Three intensities are shown: for A & B: 0.3 (brown), 0.4
(green), and 0.8 (blue) msec of light; and for C& D: 0.3 (brown), 0.5 (green), and 0.8
(blue) msec of light.
3.5 The effect of MTEP treatment on SS-ChR IPSCs in control cortex
Does MTEP treatment change the SS-ChR IPSC in controls?
For all studies on the IPSCs three measures will be presented: peak amplitude;
area of the significant response (defined as two standard deviations above the mean of
the baseline, which is the region prior to stimulation for each voltage clamp
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recording); and duration of the significant response. Each measure is plotted against
the 11 stimulus intensities (duration of bLED in msec). The plots for the comparison
between untreated controls and MTEP-treated controls are shown in Figure 6. To test
for significant differences, a 2-way repeated measure ANOVA was used with stimulus
intensity as the repeated measure. For this comparison, recordings were made from 19
untreated control and 11 control – MTEP treated neurons. There was no significant
effect of subject group or stimulus intensity, however there was a significant
interaction of these two (p=0.01, see Table 1, where all p values are reported for
comparisons shown in Figs. 6-9). For post hoc analyses of the interaction between
Figure 6. Comparison of the SS-ChR
evoked IPSC between untreated
(naïve) controls (black, N = 19) and
MTEP-treated sham-injured controls
(purple, N = 11). Does MTEP alone
have an effect? IPSCs were recorded
in layer V pyramidal neurons in
tissue with ChR selectively in SS
interneurons. Stimulus intensity was
generated via increasing durations of
bLED. The IPSC peak amplitude (A),
area of significant response (B), and
duration of significant response (C)
are shown here. Significance was
tested with a 2-way repeated
measures ANOVA. For peak and
area, there was no significant
difference between subject groups
and no significant interaction
between subject groups and stimulus
intensity. * = significant difference
assessed with post hoc analysis. See
text and Table 1 for all p values.
subject group and stimulus intensity, in all cases a 1-way ANOVA was performed at
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each stimulus intensity, with the p value adjusted with a Bonferroni correction
(0.05/number of comparison tests). In this case there were 11 stimulus intensities, so
in order to reach significance at any one level, the p value had to be less than 0.045
(0.05/11). After applying these criteria, there was no significant difference in the peak
IPSC between control-untreated and control-MTEP at any stimulus level.
The area of the IPSC was not significantly different for MTEP-treated
compared to untreated controls, there was also no effect of stimulus intensity and the
interaction was also not significant (see table 1). For IPSC duration, there was an
effect of group, an effect of stimulus intensity, and an interaction (p<0.05). To further
examine the interaction, 1-way ANOVAs were performed at each level, with a
Bonferroni adjustment to the p value needed for significance. After applying this
correction, there was a significant difference between control-untreated and controlMTEP only at 0.2, 0.3 and 0.4 msec stimulus intensity levels, as shown by asterisks in
Fig. 6.
3.6 Does MTEP prevent the PMR-associated increase in SS-ChR IPSC peak?
To determine if MTEP could prevent the PMR-associated increase in the peak
of the IPSC evoked with optogenetic activation of SS interneurons, we first compared
the results between control-MTEP and PMR-MTEP groups. Should MTEP be
effective, it was expected that there would no longer be a significant difference
between control and PMR when both were treated with MTEP. That was in fact the
case, based on a 2-way ANOVA for just these groups (subject groups N.S. different,
p>0.05). However it is possible that even without a significant difference that MTEP
was not returning the SS interneuron output to the normal (untreated control) levels.
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To examine this further, the results for four groups: control-untreated (19
neurons), PMR-untreated (14 neurons), control-MTEP (11 neurons) and PMR-MTEP
(11 neurons, see Figure 7) were compared. For IPSC peak, although there was no
effect of subject group with the 2-way repeated measures ANOVA, there was a
significant effect for stimulus intensity and a significant interaction between stimulus
intensity and subject group (p<0.05). To determine which subject groups were
significantly different for which intensities, 1-way ANOVAs with Bonferroni
correction to the p-value were used (as described above). This analysis showed a
significant group effect for three intensities: 0.2, 0.3, and 0.4 msec. Bonferroni post

Figure 7. Does MTEP prevent
the enhanced SS-ChR IPSC
associated with the PMR? All
features are the same as for
figure 6, with 14 PMRuntreated neurons and 11 PMRMTEP neurons. There was a
significant interaction between
subject group and stimulus
intensity on all measures (twoway repeated measures
ANOVA, p<0.05). MTEP
treated groups were larger than
untreated groups at low
intensities. See text and Table 1
for further explanation of
significant effects.
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hoc analysis of this result showed that the PMR-MTEP group was significantly larger
than the control-untreated and PMR-untreated groups at all three intensities.
It is however clear that to draw firm conclusions, additional data will be
necessary, given the large error bars and low power (see power in Table 1) associated
with the current data. Results for IPSC area were similar to those for IPSC peak with
significant effects of stimulus intensity and the interaction between subject group and
stimulus intensity. The post hoc analysis showed that only at 0.2 msec was there a
significant difference, where PMR-MTEP was once again greater than both controluntreated and PMR-untreated. For the IPSC duration the results were similar to that
for peak. The 2-way repeated measures ANOVA showed a significant effect of
stimulus intensity and a significant interaction between subject groups and stimulus
intensity. Post hoc analyses at each intensity showed a significant group effect only for
the 0.2 and 0.3 msec stimuli. At those levels, the PMR-MTEP group was greater than
both the control-untreated and the PMR-untreated groups. In addition, the controlMTEP group was also greater than the PMR-untreated group at both intensities and
greater than the control-untreated group at 0.2 msec.
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3.7 The effect of GBP treatment on SS-ChR IPSCs in control cortexTo determine
if the second potential treatment, that with GBP had a direct effect on the SS-ChR
IPSC, we compared the untreated controls to the GBP-treated controls (Figure 8). We
again used a 2-way repeated measures ANOVA to test for significant differences (N =
19 and 7 neurons for untreated and GBP). There was no significant effect of subject
group and no significant interaction, but there was a significant effect of stimulus
intensity (p<0.05). The same was true for measures of IPSC area and duration, where
there was no significant difference between control-untreated and control-GBP and no
significant interaction between stimulus intensity and subject group, but there was a
significant effect of stimulus intensity.

Figure 8. Does GBP affect the
SS-ChR IPSC in control cortex?
Untreated controls in black (N
= 19) and GBP-treated controls
in blue (N = 7). Measures of
peak (A); area (B); and
duration (C) of the IPSC are
shown. A 2-way repeated
measures ANOVA was used to
test for significance. There was
a significant effect of stimulus
intensity only, for all three
measures.

50

3.8 Does GBP prevent the PMR-associated increase in SS-ChR IPSC peak?
To determine if GBP could prevent the PMR-associated increase in the peak of
the IPSC evoked with optogenetic activation of SS interneurons, we first compared the
results between control-GBP and PMR-GBP groups. Should MTEP be effective, it
was expected that there would no longer be a significant difference between control
and PMR when both were treated with GBP. That was in fact the case, based on a 2way ANOVA for just these groups (subject groups N.S. different, p>0.05). However it
is possible that even without a significant difference that GBP was not returning the
SS interneuron output to the normal (untreated control) levels.
To examine this further, the results for four groups: untreated controls (19
neurons), untreated PMR (14 neurons), control-GBP (7 neurons) and PMR-GBP (11
neurons, see Figure 9) were compared. For IPSC peak, although there was a
significant effect of subject group with the 2-way repeated measures ANOVA, there
was a significant effect for stimulus intensity and also a significant interaction
between stimulus intensity and subject group (p<0.05). Once there is an interaction,
we have investigated this statistically, rather than examining the differences between
subject groups. Post hoc analyses of the interaction were performed as described
above, with 1-way ANOVAs at each intensity, with a Bonferroni correction applied to
the p value. For peak IPSC, there was a significant group effect at stimulus intensities
0.2, 0.3 and 0.4 msec. At these levels the PMR-GBP group was significantly larger
than both control-untreated and PMR-untreated groups. In addition, the control-GBP
group was significantly larger than the PMR-untreated group at the 0.3 msec stimulus
intensity.
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For the area of the IPSC, there was an effect of stimulus intensity and an
interaction between subject group and stimulus intensity. Post hoc analysis using 1way ANOVAs with Bonferroni correction applied to the p-value showed a significant
effect of group for intensities 0..1, 0.2 and 0.3 msec. At these intensities, the PMRGBP group was significantly larger than control-untreated and PMR-untreated groups.
In addition at the 0.2 msec level, the control-GBP group was significantly larger than
PMR-untreated group.
For the duration of the IPSC, the 2-way repeated measures ANOVA showed an
effect of subject group, stimulus intensity and a significant interaction between these
two. We again focused on the interaction to further understand these results. Post hoc
analyses of 1-way ANOVAs at each stimulus intensity with Bonferroni correction
applied to the p value, showed significant group effects at the 0.2, 0.3, and 0.4 msec
levels. At these levels, the PMR-GBP group was significantly larger than both the
control-untreated and the PMR-untreated groups. In addition, at the 0.2 and 0.3 levels,
the control-GBP was also significantly larger than both the control-untreated and
PMR-untreated groups. It is however still clear that to draw firm conclusions,
additional data will be necessary, given the large error bars and low power (see Table
1) associated with the current data.
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Figure 9. Does GBP prevent
the enhanced SS-ChR IPSC
associated with the PMR? All
features are the same as for
figure 8, with the addition of 14
PMR-untreated neurons and 11
PMR-GBP neurons. There was
a significant interaction
between subject group and
stimulus intensity on all
measures (two-way repeated
measures ANOVA, p<0.05. See
text and Table 1 for further
effects.

3.9 Is GBP more effective than MTEP in reducing the SS-ChR IPSC?
While it is clear that for all four drug-treated groups additional neurons are
needed to complete this project, here we attempted to compare the GBP and MTEP
effects for this preliminary form of the data. To make direct comparisons of the effect
of the drug on the PMR-associated changes, all PMR data was normalized to the mean
of its respective control. For instance, each untreated PMR peak IPSC value was
divided by the mean of the untreated control peak IPSC. This was repeated for MTEP
and GBP groups. Thus for any given value if the PMR IPSC value was equal to that of
the control, this procedure would yield a normalized value of 1. The results for the
three measures of peak, area, and duration of the IPSC are shown in Figure 10. For
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the untreated group, the peak and the area of the IPSC was 3-4 times that of control on
intensities of 0.5 msec and greater. In contrast, for both MTEP and GBP, the values
were between 1 and 2 on the normalization scale, further demonstrating the lack of
difference between control and PMR in the drug-treated groups. This figure shows that
MTEP and GBP were not significantly different in their effectiveness. To test for
significance, 2-way repeated measures ANOVAs were again used. The p values and
observed power for this data is reported in Table 2.

Figure 10. All PMR data
normalized to their respective
controls. MTEP and GBP are
equally effective in reducing the
enhanced SS-ChR IPSC in
malformed brain. Measures of peak
(A), area (B) and duration (C)
shown. Untreated in green (N =
14); MTEP in pink (N = 11); and
GBP in blue (N=11). See Table 2
for 2-way repeated measures
ANOVA p values and observed
power for the data shown here.
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Table 1. p values and observed power in parentheses for all comparisons tested with a
2-way repeated measures ANOVA shown in figures 6-9. Comparison groups are listed
from left to right. IPSC measures of peak, area and duration are listed from top to
bottom, respectively. Significant differences (p<0.05) shown in red. For these
comparisons, N = 19 untreated control, 14 untreated PMR, 11 control-MTEP, 11 PMRMTEP, 7 control-GBP, and 11 PMR-GBP
Table 2. p values and observed power in
parentheses for the comparisons shown in Fig.
10 and tested with 2-way repeated measures
ANOVA. These data were normalized to the
mean of their respective controls. IPSC measures
of peak, area and duration are listed from top to
bottom, respectively. Significant differences
(p<0.05) shown in red. For these comparisons, N
= 14 PMR-untreated, 11 PMR-MTEP, and
11PMR-GBP neurons.
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Chapter 4
Discussion

Epilepsy has been previously attributed to increased excitation or decreased
inhibition. With this frame of mind, modern medicine has been unable to develop an
effective permanent treatment against the mechanisms of epilepsy for some patients. In
order to treat patients with intractable seizures, especially those caused by developmental
malformations, it is essential to understand the entirety of mechanisms that could
possibly play a role in the abnormal cortical function. Excitatory afferents are increased
in the PMR due to the presence of the microgyrus (Jacobs and Prince 2005). This
suggests that the hyperexcitability is caused by these extra glutamatergic synapses;
however, the early susceptibility to excitation does not coincide with the increased
excitation onto pyramidal neurons and may actually be caused by changes in inhibitory
interneurons (George and Jacobs 2006, George and Jacobs 2011, Bell and Jacobs 2014).
This suggests a role for GABAergic interneurons in epileptogenesis. Previous studies
have shown that excitation persists even with enhanced inhibitory function suggesting
that the inhibition is not decreasing excitation in the network; blocking of the inhibition
causes a decrease in epileptiform activity in some epilepsies or conditions (Mann and
Mody 2008). It was shown that in the PMR region, SS interneurons have an increased
output compared to PV interneurons (George and Jacobs 2011). In addition, it has been
shown that the mGluR5 receptor is enhanced in its presence in the PMR region in FL
animals as opposed to control on these SS interneurons.
The overall goal of this study was to determine if blockade of the mGluR5 receptor
would inhibit the output from SS interneurons and therefore decrease the overall
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excitation seen in the FL model. With the use of field potential recordings and
optogenetics with patch clamping the following observations were made:
Patch clamping was used to measure the output of the SS interneurons by selectively
activating them with blue light using optogenetics. Field potential recordings were used
in order to determine the presence of epileptiform activity in our experimental groups.
MTEP was used on PMR and SHAM mice in order to reduce the output from the SS
interneurons by blocking the mGluR5 receptor, and therefore, the overall
hyperexcitability seen in the FL model. GBP was used as a drug control and was also
used to treat PMR and SHAM mice. GBP blocks the interaction of TSP and the α2δ-1
receptor and therefore inhibits excitatory synapse formation.
There was epileptiform activity seen in all groups, even in untreated mice. It is
normal, however, for untreated mice to have a certain amount of epileptiform activity due
to high concentrations of NMDA receptors and not fully developed GABAergic systems
(Luhmann and Prince 1990).
In untreated PMR mice, the incidence of epileptiform activity is higher within the
PMR than in homotopic control cortex. This is similar to what’s seen in the rat FL model.
This increased amount of epileptiform activity in the PMR mice compared to controls
suggests a developmental change.
Results also showed a high rate of epileptiform activity in MTEP SHAM mice
compared to untreated PMR mice. The incidence of epilepsy per slice in MTEP PMR
mice was lower than MTEP SHAM mice. This suggests that MTEP decreases
epileptiform activity, however, it also suggests that MTEP affects another aspect of the
brain due to the high rate of epileptiform activity in the MTEP SHAM mice compared to
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untreated PMR mice. The fact that epi incidence in slices from MTEP PMR mice was
decreased– especially as compared to untreated PMR mice – suggests that MTEP may in
fact be effective in reducing the malformation-associated causes of hyperexcitability.
MTEP-treated controls did not differ from the untreated controls in peak, area, or
duration of IPSCs at the longer light durations. The only difference was seen in the initial
intensities (0.2, 0.3, 0.4 msec) for the IPSC duration. For MTEP PMR and control vs
untreated PMR and control, there was a significant interaction between the groups at
intensities 0.2, 0.3, and 0.4 msec light duration for the peak, at 0.2 msec in the IPSC area
for MTEP PMR vs untreated groups and 0.2 and 0.3 msec for IPSC duration for MTEP
PMR vs untreated groups. We currently do not know why there is increased SS
interneuron output at these low intensities, however, future studies will look into this
aspect. Some potential causes of the increased output could be technical error, possible
biological differences in current mice, or a biological change due to MTEP in the cortex
or elsewhere.
An explanation for the amount of epileptiform activity is possibly due to MTEPs
role in excitatory or inhibitory neuron formation. When mGluR5 is knocked out, cortical
excitatory neurons receive reduced inhibitory inputs into layer IV, suggesting a role for
mGlu5 in the functional development of GABAergic circuits (Ballester-Rosado, Albright
et al. 2010). Additionally, mGluR5 plays an important role in radial-glial-mediated
neuronal guidance which is important for normal neocortical function (Louhivuori,
Jansson et al. 2014) so the blocking of this receptor could have detrimental effects. They
showed that the interruption of the mGlu5 receptor hinders the activity of the canonical
transient receptor potential (TRPC) channel family which has been shown to mediate the
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responses of growth cones to guidance cues through their control of calcium currents.
This in turn effects radial glial mediated neuronal guidance and may have an impact on
specific neurons that are in the layers of the neocortex (Louhivuori, Jansson et al. 2014).
This could affect the formation of the PMR because of the formation of the microgyrus
and subsequent redirected afferents.
The mGluR5 receptor on SS interneurons was specifically targeted due to
previous work demonstrating its enhanced presence in the PMR, but not in control.
Previous studies in our lab have shown that these SS interneurons are more active in the
PMR region and could be the cause of the hyperexcitability caused by the synchronous
firing of pyramidal neurons due to SS interneuron synchronous inhibition.
The fact that GBP-treated SHAM were similar to untreated controls in their epi
incidence suggests that GBP has no effect on normal network excitability. GBP also
appeared to have no effect on FL-induced hyperexcitability, since GBP PMR was similar
to untreated PMR mice. This, however, is opposite of what was found in Andersen
(2014). What could explain the difference in results could be the age that lesions were
done as well as the severity of the lesion. We do a bilateral lesion as compared to a
unilateral lesion and our mice had the FL at age P1 instead of P0. Andersen (2014) found
no difference in the amount of epileptiform activity in GBP treated FL animals compared
to SHAM injured animals (Andresen, Hampton et al. 2014), concluding that GBP was
able to reduce in vitro cortical hyperexcitability after an induced FL.
The effects of GBP treatment showed significant effects at low intensities of IPSC
peak, duration, and area in the GBP PMR group compared to the untreated groups.
Again, it is not known why there is increased SS interneuron output at these low
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intensities, however, future studies will look into this aspect. Additionally, there was no
difference seen in the SS interneuron output in GBP PMR or GBP SHAM groups when
compared.
Translation and relevance of project:
Current AEDs cause either a decrease in excitation, like GBP, or cause an increase in
inhibition. Most AEDs work fairly well, but not all seizures are treatable with these
AEDs. The alternative when AEDs do not work is invasive surgery. AEDs also generally
have problems such as problematic drug interaction and other aversive side effects and do
not work well in patients with PMG. Targeting the mGluR5 receptor is attractive due to
the fact that this receptor is not normally expressed in high amounts in normal control
tissue. Because of this, MTEP, an mGluR5 receptor antagonist, may not cause the
extensive side effects as other AEDs. MTEP blockade of the mGlu5 receptor shows
promise in its ability to decrease SS interneuron output, however, further experimentation
is needed. This type of mechanism, if translatable to humans, could result in a successful
treatment for previously intractable epilepsies associated with developmental
malformations.
These experiments showed that there is a possible role of the mGluR5 in the decrease
in epileptiform activity caused by developmental malformations, however, additional
drug experiments need to be done to determine MTEP’s efficiency in aiding in this
process.
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Further directions:
Further investigation into the mechanisms of SS interneuron maturation will help
further narrow down the areas to which treatments can be applied. One possibility is
different maturation times. Knowing the mechanisms of SS interneuron maturation would
be a helpful study in order to determine why they have increased expression of mGluR5.
Further studies involving the drug, rapamycin, an mTOR pathway inhibitor, would be
a promising next step. The mTOR pathway is one of many pathways activated by the
mGlu5 receptor. MTOR is a rapamycin-sensitive serine-threonine kinase that plays a role
in mRNA translation initiation, consequently affecting cell growth, dendritic arborization,
neuronal morphology, proliferation, and cortical development (Meyuhas 2000, Chen,
Atkins et al. 2007, Nguyen, Brewster et al. 2015). Due to MCDs being linked to problems
in genes encoding known regulators of the mTOR pathway, blocking this pathway seems
to be a logical step in potential treatments (Nguyen, Brewster et al. 2015). Because
mGluR5 has been shown to be important in development, narrowing down treatment to a
specific pathway activated by this receptor might be the key to a potential therapeutic
treatment for intractable epilepsies in order for the partial function of this receptor to
remain intact. Additionally, mTOR is a promising next step because some studies have
shown that in seizures that are difficult to treat, MTEP’s use to block the mGlu5 receptor
is ineffective (Witkin, Baez et al. 2008).
There are many future directions to be taken in order to elucidate the role of mGluR5
in the increased output from SS interneurons. Due to the complexity of the cascading
pathways activated by this receptor, there needs to be further experimentation in order to
determine a specific mechanism to control these SS interneurons.
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